News from Dar Al Dawa Group

December 2001

Dar Al Dawa, the First Pharmaceutical Company in Jordan to be Awarded the ISO 9001:2000 Certificate

Dar Al Dawa was recently granted the ISO 9001:2000 certificate from SGS. Being the first pharmaceutical company and the ninth in Jordan, Dar Al Dawa is proud to announce that such an achievement is the result of its continuous efforts to adhere to world-wide quality systems and its solid commitment to attain customer satisfaction.

 

Dar Al Dawa Remains on the Top of the Sales Pyramid in Jordan IMS for the Fourth Consecutive Year

For the fourth year in a row, and according to the IMS reports, Dar Al Dawa's sales in values are ranked first amongst all pharmaceutical companies in Jordan (local and multinationals). Furthermore, three out of the top five selling products are Dar Al Dawa's, namely Diclogesic (diclofenac), Famodar (famotidine), and Cloracef (cefaclor).

Dr. Mohammad Fityani, the Managing Director of Dar Al Dawa, stated that such an achievement is mainly due to the coherence of best quality products and proper marketing expertise. Dr.Fityani added: "we are taking the necessary steps to accomplish similar level of distinction in other areas of the Middle East and North Africa".

The table below shows the sales position of Dar Al Dawa with respect to the leading Jordanian pharmaceutical manufacturers:

All values are in Jordanian Dinar (USD = 0.708 JOD)

Company

12M Q.IV 98

12M Q.IV 99

12M Q.IV 00

12M Q.I 01

12M Q.II 01

12M Q.III 01

 

Value
+00

Rank

Value
+00

Rank

Value
+00

Rank

Value
+00

Rank

Value
+00

Rank

Value
+00

Rank

Dar Al Dawa (DAD) 4,767.7 1 4,030.8 1 4,100.0 1 1,404.6 1 1,563.6 1 1,214.8 1
Al-Hikma 4,096.3 2 3,521.5 3 3,582.4 2 1,096.1 2 1,151.9 3 774.4 4

Arab Pharmaceutical Manufacturing Co. (APM)

3,880.8

3

3,921.3

2

3,546.3

3

612.5

5

1,242.5

2

711.2

5

Where 12M Q.IV 00 means: results of last twelve months sales in fourth quarter IMS report for year 2000.

 

back to news archives

 

 
 

home | jobs | news | site map | contact us | feedback